Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Scios Nova's Auriculin

Executive Summary

Scios Nova's Auriculin: Preliminary results of a Phase III acute renal failure trial show no difference between patients treated with the atrial natriuretic peptide and those who received placebo in the need for dialysis or mortality, the company reports May 3. Scios said the company and its partner Genentech will further evaluate the data but believe that additional clinical studies will be required for an NDA submission. "We will not meet our objective of filing an application in 1995 for marketing approval," the firm says. Results of the trial will be presented at the International Congress of Nephrology in Madrid, Spain in July. Genentech announced in January that it would be investing up to $100 mil. in Scios Nova's Auriculin R&D...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel